Lifeward Ltd. (LFWD)
NASDAQ: LFWD · Real-Time Price · USD
1.765
-0.075 (-4.08%)
At close: Feb 21, 2025, 4:00 PM
1.830
+0.065 (3.68%)
After-hours: Feb 21, 2025, 6:08 PM EST
Lifeward Revenue
Lifeward had revenue of $6.13M in the quarter ending September 30, 2024, with 39.18% growth. This brings the company's revenue in the last twelve months to $25.00M, up 173.28% year-over-year. In the year 2023, Lifeward had annual revenue of $13.85M with 151.39% growth.
Revenue (ttm)
$25.00M
Revenue Growth
+173.28%
P/S Ratio
0.61
Revenue / Employee
$231,500
Employees
108
Market Cap
18.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13.85M | 8.34M | 151.39% |
| Dec 31, 2022 | 5.51M | -455.00K | -7.63% |
| Dec 31, 2021 | 5.97M | 1.57M | 35.81% |
| Dec 31, 2020 | 4.39M | -480.00K | -9.85% |
| Dec 31, 2019 | 4.87M | -1.67M | -25.55% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
LFWD News
- 3 days ago - Lifeward Announces CEO Transition - GlobeNewsWire
- 5 weeks ago - Lifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities - GlobeNewsWire
- 5 weeks ago - Lifeward Cancels Its Extraordinary General Meeting of Shareholders - GlobeNewsWire
- 6 weeks ago - Lifeward Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 6 weeks ago - Lifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Lifeward Announces Postponement of its Extraordinary General Meeting of Shareholders - GlobeNewsWire
- 3 months ago - Coverage for ReWalk Personal Exoskeleton Expands as Hungary Joins the U.S. and Germany with a Policy Providing Access to Exoskeletons - GlobeNewsWire
- 3 months ago - Lifeward Ltd. (LFWD) Q3 2024 Earnings Call Transcript - Seeking Alpha